Cover Image

Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities

Model‐informed drug development (MIDD) approaches have rapidly advanced in drug development in recent years. Additionally, the Prescription Drug User Fee Act (PDUFA) VI has specific commitments to further enhance MIDD. Tumor growth dynamic (TGD) modeling, as one of the commonly utilized MIDD approac...

Full description

Saved in:

Bibliographic Details
Main Authors:	Nidal Al‐Huniti (Author), Yan Feng (Author), Jingyu (Jerry) (Author), Zheng Lu (Author), Mario Nagase (Author), Diansong Zhou (Author), Jennifer Sheng (Author)
Format:	Book
Published:	Wiley, 2020-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Modeling Tumor Growth and Treatment Resistance Dynamics Characterizes Different Response to Gefitinib or Chemotherapy in Non‐Small Cell Lung Cancer
by: Mario Nagase, et al.
Published: (2020)

On the Regulatory Approval Pathway of Biosimilar Products
by: Jun Wang, et al.
Published: (2012)

The South African Regulatory System: Past, Present, and Future
by: Andrea Keyter, et al.
Published: (2018)

Approved HIV reverse transcriptase inhibitors in the past decade
by: Guangdi Li, et al.
Published: (2022)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
by: Ioana Gherghescu, et al.
Published: (2020)

Access to Chagas disease treatment in the United States after the regulatory approval of benznidazole.
by: Kota Yoshioka, et al.
Published: (2020)

The Labyrinth of Product Development and Regulatory Approvals in Liquid Biopsy Diagnostics
by: Federico M. Goodsaid
Published: (2019)

Contemporary oncology trials, drug approvals and the physician-patient relationship
by: John-John B. Schnog, et al.
Published: (2022)

Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP‐5862, Using a Physiologically‐Based Pharmacokinetic Modeling Approach
by: Diansong Zhou, et al.
Published: (2019)

Mesenchymal Stem Cell Therapies Approved by Regulatory Agencies around the World
by: Luis E. Fernández-Garza, et al.
Published: (2023)

Characteristics of Single Pivotal Trials Supporting Regulatory Approvals of Novel Non‐orphan, Non‐oncology Drugs in the European Union and United States from 2012−2016
by: Anne Vinther Morant, et al.
Published: (2019)

The Oncology Clinical Research Nurse Study Co-Ordinator: Past, Present, and Future
by: Elizabeth Ness
Published: (2020)

Regulatory lessons from China's COVID-19 vaccines development and approval policies
by: Jingshu Yang, et al.
Published: (2022)

Regulatory reliance to approve new medicinal products in Latin American and Caribbean countries
by: Carlos E. Durán, et al.
Published: (2021)

Emerging technology trends in regulatory approvals of cancer immunotherapy drugs by the FDA and EMA
by: Maryam Monajati, et al.
Published: (2024)

Analysis of the Regulatory Science Applied to a Single Portfolio of Eight Biosimilar Product Approvals by Four Key Regulatory Authorities
by: Beverly Ingram, et al.
Published: (2021)

Regulatory framework of the oncological medical care provision
by: S. N. Tishkina, et al.
Published: (2020)

FDA regulatory considerations for oncology drug development
by: Hanlim Moon, et al.
Published: (2024)

Biosimilars in Oncology: Latest Trends and Regulatory Status
by: Deeksha Joshi, et al.
Published: (2022)

Turning data into better mental health: Past, present, and future
by: Nidal Moukaddam, et al.
Published: (2022)

Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics
by: Valentina Tateo, et al.
Published: (2023)

Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States
by: Robert Roskoski Jr
Published: (2023)

Theology at the University of Pretoria - 100 years: (1917-2017) Past, present and future
by: Pilay, Jerry
Published: (2017)

Theology at the University of Pretoria - 100 years: (1917-2017) Past, present and future
by: Pilay, Jerry
Published: (2017)

Quantitative Approach to Explore Regulatory T Cell Activity in Immuno-Oncology
by: Alejandro Serrano, et al.
Published: (2024)

A multistate platform model for time‐to‐event endpoints in oncology clinical trials
by: Chih‐Wei Lin, et al.
Published: (2024)

Target-controlled infusion - Past, present, and future
by: Prasanna Udupi Bidkar, et al.
Published: (2024)

Growth in floor area: the blind spot in cutting carbon [version 1; peer review: 1 approved, 2 approved with reservations]
by: David Ness
Published: (2020)

Oncology Nursing in Hong Kong: Milestones over the Past 20 Years
by: Suzanne So-Shan Mak
Published: (2019)

Opportunities and challenges for verbal autopsy in the national Death Registration System in Sri Lanka: past and future
by: Gunesekera EM, et al.
Published: (2011)

Comparison of pharmacogenomic information for drug approvals provided by the national regulatory agencies in Korea, Europe, Japan, and the United States
by: Mijin Lee, et al.
Published: (2023)

Population pharmacokinetic modeling and simulation of maribavir to support dose selection and regulatory approval in adolescents with posttransplant refractory cytomegalovirus
by: Kefeng Sun, et al.
Published: (2023)

The Dynamics of Opportunity in America Evidence and Perspectives /
Published: (2016)

Opportunities for ovarian reserve preservation in the treatment of oncological diseases
by: Juliia E. Dobrokhotova, et al.
Published: (2020)

The FDA's New Guideline "Generally Accepted Scientific Knowledge" (GASK): An Opportunity to Expedite the Approval of Biosimilars
by: Sarfaraz K. Niazi
Published: (2023)

Dynamics of physical and functional status of students in the experiment on approvals personality oriented physical education
by: S.I. Belykh
Published: (2013)

Dynamics of physical and functional status of students in the experiment on approvals personality oriented physical education
by: Belykh S.I
Published: (2013)

Clinical pharmacology information in regulatory submissions and labeling: A comparative analysis of orphan and non‐orphan drugs approved by the FDA
by: Julie Hsieh, et al.
Published: (2022)

Lessons from gefitinib-induced interstitial lung disease in Japan: Problems in approval, pharmacovigilance, and regulatory decision-making procedures
by: Nishimura T, et al.
Published: (2006)

The development of China's vaccine industry in the past decade: the perspective from drug regulatory science
by: Guanjie Wang, et al.
Published: (2021)